Walthausen & Co’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$1.41M Sell
23,270
-13,904
-37% -$898K 1.18% 34
2022
Q2
$2.04M Buy
37,174
+3,130
+9% +$181K 0.91% 29
2022
Q1
$2.57M Sell
34,044
-970
-3% -$66.3K 0.73% 62
2021
Q4
$2.61M Sell
35,014
-17,600
-33% -$1.04M 0.69% 72
2021
Q3
$2.47M Sell
52,614
-11,466
-18% -$499K 0.63% 88
2021
Q2
$2.59M Sell
64,080
-4,050
-6% -$168K 0.57% 94
2021
Q1
$2.8M Sell
68,130
-1,670
-2% -$62.3K 0.59% 83
2020
Q4
$2.03M Buy
+69,800
New +$1.81M 0.55% 90

Other funds holding ACLS

Walthausen & Co's ACLS Position: Q3 2022 in Review

Walthausen & Co reduced its Axcelis (ACLS) stake by 37% in Q3 2022, selling an estimated $898K and leaving 23,270 shares worth $1.41M. The position accounts for 1.18% of the portfolio, ranked #34.

Walthausen & Co first reported a position in ACLS in Q4 2020 and has held it in 8 quarters since. The position peaked at $2.8M in Q1 2021. 287 funds tracked by Wall St. Rank hold ACLS as of Q3 2022.

  • Walthausen & Co held 23,270 shares of Axcelis worth $1.41M as of Q3 2022.
  • Walthausen & Co sold 13,904 Axcelis shares in Q3 2022, an estimated $898K.
  • Axcelis made up 1.18% of Walthausen & Co's portfolio in Q3 2022, its #34 holding.
  • Walthausen & Co first reported a position in Axcelis in Q4 2020 and has held it in 8 quarters since.
  • Walthausen & Co's Axcelis position peaked at $2.8M in Q1 2021.
  • 287 funds tracked by Wall St. Rank held Axcelis as of Q3 2022.

Based on Walthausen & Co's 13F filing for Q3 2022, filed 14 Nov 2022.